CurrentCareSourcePolicy Epidural Steroid Injections-AR PASSE-MM-1504

Epidural Steroid Injections

Defines medical necessity criteria, limitations, exclusions, and procedural billing components for epidural steroid injections (translaminar/interlaminar, transforaminal, caudal) for chronic back pain for Arkansas PASSE members under CareSource.

Policy Summary

PayerCareSource

PolicyEpidural Steroid Injections

Policy CodePolicy Epidural Steroid Injections-AR PASSE-MM-1504

Change TypeReviewed/Updatedexemption added

Effective DateMar 1, 2026

Next Review Date

Key ActionDocument at least 6 weeks of active and 6 weeks of inactive conservative therapy within the past 6 months or document inability to complete active therapy; submit prior authorization and device interrogation reports when applicable.

SourceLink

POLICY UPDATE CHANGES

Policy reviewed/updated multiple times; Effective Date set to 03/01/2026 with prior reviews noted (01/31/2024, 01/15/2024, 12/03/2025).

Explicit statement that epidural steroid injections for labor and delivery or post-surgical pain do not require medical necessity review.

6Maximum injections per 12 months

3Max procedures per 12 weeks per region

2Max diagnostic injections (initial)

>=50%Required relief from prior injection to permit subsequent

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.